Disease relevance of Soft Tissue Infections

• Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature [1].
• This experience suggests that group A beta-hemolytic streptococcal bacteremia and soft-tissue infection may present in epidemic fashion among parenteral drug addicts in the absence of a common source [2].
• Epidemiological studies strongly implicate the bacterial superantigen, streptococcal pyrogenic exotoxin A (SPEA), in the pathogenesis of necrotizing soft-tissue infection and toxic shock syndrome resulting from Streptococcus pyogenes [3].
• Ninety-three female patients with post-cesarean endometritis, post-hysterectomy pelvic cellulitis, and other miscellaneous moderately severe pelvic soft-tissue infections were treated in a randomized fashion with either ticarcillin plus clavulanic acid or cefoxitin [4].
• Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment [5].

Psychiatry related information on Soft Tissue Infections

• A randomized, double-blind trial compared the clinical and bacteriologic efficacy of ampicillin/sulbactam (2 g/1 g) and cefoxitin (2 g) administered intravenously every 6 h to patients with (n=49) or without (n=47) histories of injection drug abuse who presented with cutaneous or other soft-tissue infections [6].

High impact information on Soft Tissue Infections

• Erythromycin for anaerobic pleuropulmonary and soft-tissue infections [7].
• Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection [8].
• The results implicate the hyaluronic acid capsule as a virulence factor in soft tissue infection [9].
• GM-CSF-deficient mice have a modest impairment of reproductive capacity, a propensity to develop lung and soft-tissue infections, and a similarly reduced survival as in G-CSF-deficient animals [10].
• The literature on SLE and pneumococcal soft tissue infections is reviewed [1].

Chemical compound and disease context of Soft Tissue Infections

• This study also demonstrates the efficacy of ciprofloxacin in soft tissue infection [11].
• Treatment of skin and soft tissue infections with imipenem/cilastatin [12].
• Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen [13].
• Efficacy of intravenous clindamycin and methicillin in gram-positive soft tissue infections [14].
• Noncomparative trial of ticarcillin plus clavulanic acid in skin and soft tissue infections [15].

Biological context of Soft Tissue Infections

• We studied the concentrations in plasma and pharmacokinetics of imipenem and cilastatin in elderly patients (greater than 65 years old) who had various degrees of renal function and who were hospitalized with soft tissue infections [16].
• Fba is an FHL-1 and FH binding protein expressed on the surface of the human pathogenic bacterium, Streptococcus pyogenes, a common agent of pharyngeal, skin, and soft-tissue infections [17].
• Hydrolysis of chloramphenicol succinate in local treatment of soft tissue infections [18].
• Treatment of soft tissue infections in gynecology by comparison 3 vs 7 day therapy with ciprofloxacin [19].
• Clindamycin is an effective agent for skin and soft tissue infections, however attention should be paid to the possibility of the emergence of resistance during treatment in strains with the macrolide, lincosamide and group B streptogramin (MLS(B))-inducible resistance phenotype [20].

Anatomical context of Soft Tissue Infections

• The concentrations of drug reached in various tissues suggest that fleroxacin will be particularly useful in the treatment of gastrointestinal, urinary tract, hepatobiliary, and skeletal infections and that it shows promise for the treatment of lung and soft tissue infection [21].
• Management of soft-tissue infections of the upper extremity in parenteral drug abusers [22].
• Examples include evaluation for shoulder and ankle tendon abnormalities; soft tissue infection and joint effusion; soft tissue foreign bodies; soft tissue masses, such as Baker's cyst and wrist ganglion cyst; carpal tunnel syndrome; developmental dysplasia of the hip; and other indications where MR imaging is contraindicated [23].
• Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics [24].
• She subsequently had an isolated soft tissue infection with cartilaginous involvement of the anterior chest wall due to Salmonella enterica serogroup C1 (bioserotype oranienburg) [25].

Gene context of Soft Tissue Infections

• This study evaluated the effect of cefoxitin, interferon gamma (INF-gamma), and tumor necrosis factor alpha (TNF-alpha) on the development of a polymicrobial soft-tissue infection [26].
• Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections [27].
• An outbreak of community-associated methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infection (SSTI) occurred in a college football team from August to September 2003 [28].
• OBJECTIVE: Patients with peripheral arterial occlusive disease are prone to soft tissue infections and frequently require antibiotics [29].
• The activities of HMR 3004 and HMR 3647 and comparator agents, especially macrolides, were determined by the agar dilution method against 262 aerobic and 120 anaerobic strains isolated from skin and soft tissue infections associated with human and animal bite wounds [30].

Analytical, diagnostic and therapeutic context of Soft Tissue Infections

• The objective of this open-label, randomized, multicenter study was to compare the efficacy and safety of fleroxacin, 400 mg administered orally once daily, and amoxicillin/clavulanate potassium (AMX/CP), 500 mg/125 mg administered orally three times daily, for 4-21 days to patients with skin and soft tissue infections (SSTIs) [31].
• In clinical trials involving hospitalised patients with skin/soft tissue infections (predominantly S. aureus), intravenous/oral linezolid (up to 1250 mg mg/day) produced clinical success in >83% of individuals [32].
• Ceftriaxone given as a single daily intramuscular injection is effective therapy for skin and soft tissue infections [33].
• Eighteen patients were evaluated after treatment with ceftazidime: these included nine nosocomial lower respiratory tract infections, four soft tissue infections, three bacteraemias and two bone infections [34].
• This multicenter, randomized, double-blind study was designed to compare the safety and efficacy of cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections [35].

References